Results 131 to 140 of about 4,279 (197)

Dalbavancin for Bone and Joint Infections: A Two-Center Greek Real-World Retrospective Study. [PDF]

Pathogens
Petropoulou C, Ioannou P, Eleftherakis G, Papazisi S, Davoulos C, Drosou E, Spiliopoulou A, Tsiata E, Paliogianni F, Kofteridis D, Marangos M, Assimakopoulos SF.   +11 more
europepmc   +1 more source

Budget Impact and Financial Analysis of Outpatient Dalbavancin in an Urban, Non-Teaching, Community Hospital. [PDF]

Clin Drug Investig
Raja K, Chen B, Chandra O, Patel M, Philips M.   +4 more
europepmc   +1 more source

Evaluating oritavancin for Gram-positive infections: a systematic review of on-label and off-label use. [PDF]

Drugs Context
Soriano A, Tascini C, Falcone M, Morata L, Bongiovanni M, Pea F, Viale P.   +6 more
europepmc   +1 more source

Efficacy, safety, and population pharmacokinetics of a single 1500mg dose of dalbavancin for short-term therapy in patients with chronic prosthetic joint infections. [PDF]

Antimicrob Agents Chemother
Benavent E, Lora-Tamayo J, Ulldemolins M, Pons-Oltra P, Gregoire M, Mancheño-Losa M, Hernández-Jiménez P, Meléndez-Carmona MÁ, Casals V, Roberts JA, Rigo-Bonnin R, Murillo O.   +11 more
europepmc   +1 more source

Novel lytic phages improve the antibiofilm activity of dalbavancin, daptomycin, and fosfomycin against vancomycin-resistant enterococci. [PDF]

Microbiol Spectr
Fanaei Pirlar R, Irigoyen-von-Sierakowski A, Wagemans J, Ning Y, Lavigne R, Trampuz A, Karbysheva S.   +6 more
europepmc   +1 more source

Therapeutic Drug Monitoring Versus Fixed-Interval Dosing of Dalbavancin in Implant-Associated Spinal Infections: Grand Round/A Case Study. [PDF]

Ther Drug Monit
Houwen JPA, Hakkers CS, Schweitzer VA, Bognàr T, Toren-Wielema ML, Touw DJ, de Vries Schultink AHM.   +6 more
europepmc   +1 more source

A bundle of the top 10 OPAT publications in 2024. [PDF]

Antimicrob Steward Healthc Epidemiol
Childs-Kean LM, Azimi SF, Beieler AM, Castellino L, Keller SC, Pertzborn M, Yamshchikov A, Yoke LH, Young K, Mahoney MV.   +9 more
europepmc   +1 more source

Real-World Use of Dalbavancin in Diabetic Foot Osteomyelitis: PEDDAL Study. [PDF]

J Clin Med
Núñez LM, Benito AR, Bereciartua E, Morata L, Escudero-Sánchez R, Nadal JS, Gómez-Junyent J, Botrán AS, García AMA, Del Toro López MD, Ruiz-Cabrera D, Andrino JMR, Alidrous F, Torío-Salvador M, Verdejo MÁ, Velasco Arribas M.   +15 more
europepmc   +1 more source

A Comparative Review of the Pharmacology of Dalbavancin and Oritavancin for Gram-Positive Infections: Birds of a Feather or Apples and Oranges? [PDF]

Infect Dis Ther
Hussein M, Barclay J, Baker M, Wu Y, Thombare VJ, Patil N, Murthy AB, Sharma R, Rao GG, Blaskovich MAT, Li J, Velkov T.   +11 more
europepmc   +1 more source